Newsroom

Wednesday, 06 February 2019

Arjo and BBI JMA Territory Expanded to Northern and Southern Ireland

In August 2018 Arjo and BBI (Europe) Ltd (Bruin Biometrics) signed a Joint Marketing Agreement allowing both companies to work together for the promotion of a Pressure Ulcer (PU) Prevention Solution Set combining the BBI SEM 200 Scanner and Arjo pressure ulcer interventions, including specialised beds, therapeutic surfaces and patient mobility equipment, resulting in an offering that provides real preventive healthcare for those at risk of pressure ulcers.

Following a review of that agreement we agreed that, due to the success achieved so far, the JMA territory will be expanded to include Northern & Southern Ireland.

“Arjo has a long, proud and successful record in bringing innovative and new solutions to both NHS & HSE together with Private; Long Term Care and Homecare providers. The ability to extend our work with BBI (Europe) Ltd allows us to progress our shared goal of reducing pressure ulcers.” says William Dorrian, Director, Arjo Corporate Development & Projects.

Arjo’s Pressure Ulcer & Injury Prevention Solutions enable healthcare professionals to effectively prevent and treat pressure ulcers. Our offering, including an integrated clinical approach, products, business models and aftermarket support improves patient outcomes and reduces healthcare costs.

The SEM 200 Scanner is a wireless hand-held device that objectively alerts clinicians to specific anatomical areas of a patient’s body at increased risk of pressure ulcers. The SEM 200 Scanner supports clinicians, as an adjunct to current standard of care, to identify these areas of increased risk of pressure ulcer development 5 days (median)1 earlier than visual skin assessment.

Colin Priestley, MD EMEA BBI (Europe) Ltd stated, “BBI is delighted to continue and broaden our work with Arjo, a recognised health care solutions provider. This agreement, incorporating the innovative technology of the SEM 200 Scanner, will enable healthcare practitioners across the UK & Ireland to further develop their prevention protocols as they continue to strive for pressure ulcer incidence reduction”.

The extension to the Joint Marketing Agreement will commence with immediate effect.

For further information, please contact:

For Arjo

Martyn Elcocks, Strategic Marketing Director, UKI
Tel: +44 1582 745575
E-mail: martyn.elcocks@arjo.com

For BBI

Kate Hancock, VP Marketing and Clinical Communications, North America and EMEA
Tel: +44 7827 315347
E-mail: khancock@bruinbiometrics.com


About Arjo

At Arjo, we are committed to improving the everyday lives of people affected by reduced mobility and age-related health challenges. With products and solutions that ensure ergonomic patient handling, personal hygiene, disinfection, diagnostics, and the effective prevention of pressure ulcers and venous thromboembolism, we help professionals across care environments to continually raise the standard of safe and dignified care. Arjo has approximately 6,000 employees worldwide and customers in over 100 countries. In 2017, Arjo sales amounted to approximately SEK 7.7 billion. Arjo is listed on Nasdaq Stockholm and its head office is located in Malmö, Sweden. Everything we do, we do with people in mind. www.arjo.com

About BBI:

BBI (Bruin Biometrics), is a pioneer in modernising health care with biometric sensor technology for early detection and monitoring of chronic, preventable conditions in collaboration with clinicians. BBI has been the recipient of multiple awards with recognition from organisations such as Journal of Wound Care, Health Service Journal and Frost & Sullivan. BBI is based in Los Angeles and has its European office in Manchester, UK.

For additional information, visit www.sem-scanner.com

References

1. Okonkwo H. Milne J. et al. (2018) Evaluation of a novel device using capacitance of the detection of early pressure ulcers (PU), a multi-site longitudinal study

FaLang translation system by Faboba